Wells Fargo lowered the firm’s price target on Kymera Therapeutics (KYMR) to $53 from $57 and keeps an Overweight rating on the shares. Sanofi’s (SNY) shifting from KT-474 to KT-485 is a modest disappointment, but will mostly just push timelines for a program that Kymera receives only economics for, the analyst tells investors in a research note. The firm sees limited downside and no risk to KT-621.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Optimistic Outlook for Kymera Therapeutics Amid Strategic Partnerships and Strong KT-621 Prospects
- Closing Bell Movers: Micron surges on earnings, retreats on call comments
- Kymera Therapeutics announces $250M common stock offering
- Kymera weakness a buying opportunity, says Stifel
- Morning Movers: General Mills dips following fourth quarter report